Global transcriptional profiling demonstrates the combination of type I and type II interferon enhances antiviral and immune responses at clinically relevant doses.

A role for type II interferon (IFN-gamma) in resolving viral infection is suggested by the correlation of hepatitis C virus (HCV) clearance with enhancement of IFN-gamma-producing activated T cells in the resolution of acute HCV infection. Using vesicular stomatitis virus (VSV), a synergistic direct antiviral effect was documented using IFN-gamma1b and a potent, consensus type I IFN (IFN alfacon-1). Global expression profiling following EC50 exposure to IFN alfacon-1, IFN-gamma1b, or a cocktail of the two allowed the antiviral state to be correlated with induction of a subset of IFN-stimulated genes (ISGs). Genes identified through this analysis corresponded to classic antiviral components, ISGs more recently associated with direct antiviral functions, as well as expressed sequence tags (ESTs) and hypothetical proteins. The magnitude of these antiviral EC50-correlated expression events in human hepatoma (Huh7) cells exposed to clinically relevant doses of IFN alfacon-1, IFN-gamma1b, or a cocktail of the two was also probed because the standard of care for patients with chronic hepatitis C is type I IFN-containing regimens. Relative to type I IFNs used alone, the addition of type II IFN caused enhanced expression not only of many of the genes correlated with the direct antiviral state but also of genes involved in (1) antigen presentation to cytotoxic T lymphocytes (CTLs), (2) macrophage, natural killer (NK), and T helper 1 (Th1) cell recruitment and activation, (3) complement system function, (4) apoptosis, and (5) ISGs with unknown functions. As many of these processes are correlated clinically with resolution of chronic HCV infection, the combined use of these IFNs could display a beneficial effect on viral clearance in patients infected with HCV and other viruses through enhancement of one of these processes or of the direct antiviral state.     

FOLFOX4与替加氟替代方案对晚期胃癌疗效的对比研究

目的:对比观察FOLFOX4方案与替加氟替代方案治疗晚期胃癌的疗效和不良反应.方法:经病理或细胞学确诊的晚期胃癌患者75例,按收治的时间顺序交叉分入FOLFOX4组(A组)或替加氟替代组(B组),两方案均至少连用3周期评价疗效.A组:OXA 85mg/m2,静滴2h,第1天;LV 200mg/m2,静滴2h,第1、2天;5-FU 400mg/m2,静推,然后600mg/m2,22h静脉维持,第1、2天;2周重复,14天为1个周期.B组:OXA 130mg/m2,静滴2h,第1天;LV 200mg/m2,静滴2h,第1-5天;FT-207 800mg/m2,静滴3h,第1-5天;3周重复,21天为1个周期.结果:研究对象共75例.A组39例,总有效率(CR + PR)41.0%,其中初治患者总有效率55.6%;复治患者的总有效率28.6%.B组36例, 总有效率38.9%,其中初治患者总有效率 50.0%;复治患者的总有效率30.0%.两组总有效率比较均无统计学差异.不良反应主要是白细胞减少、恶心呕吐、神经感觉毒性等,A组白细胞下降发生率和消化系统不良反应发生率均明显高于B组(P均＜0.05).两组均无化疗相关死亡.结论:FOLFOX4方案与替加氟替代方案均为治疗晚期胃癌有效的方案,FOLFOX4方案总有效率稍高,不良反应较替加氟替代方案重,但可耐受.建议晚期胃癌初治可选用FOLFOX4方案,而其中年龄偏大,体质欠佳的患者宜选替加氟替代方案.     

脂质体阿霉素为主方案治疗高龄非霍奇金淋巴瘤的临床研究

目的 观察脂质体阿霉素联合治疗高龄非霍奇金淋巴瘤患者的有效性和安全性.方法 应用脂质体阿霉素联合COP为主的方案化疗或联合利妥昔单抗等其他治疗方案治疗34例患者,观察患者应用脂质体阿霉素过程中及其后的毒副反应及疗效.结果 全组34例患者共接受176个疗程化疗,平均每个患者累计应用脂质体阿霉素127.0 mg治疗,总有效率(CR+PR)为88.2%(30/34),其中CR 24例(70.6%),PR 6例(17.7%),SD 1例(2.9%),PD 3例(8.8%).毒副反应主要为骨髓抑制,未出现严重感染.心脏毒性发生率14.7%(5/34),无化疗相关死亡.结论 脂质体阿霉素联合治疗高龄非霍奇金淋巴瘤具有较高的安全性和有效性.     

Endoscopic pH monitoring for patients with suspected or refractory gastroesophageal reflux disease.

BACKGROUND: Wireless pH studies can offer prolonged pH monitoring, which may potentially facilitate the diagnosis and management of patients with gastroesophageal reflux disease (GERD). The aim of the present study was to evaluate the detection rate of abnormal esophageal acid exposure using prolonged pH monitoring in patients with suspected or refractory GERD symptoms. METHODS: Patients undergoing prolonged ambulatory pH studies for the evaluation of GERD-related symptoms were assessed. Patients with a known diagnosis of GERD were tested on medical therapy, while patients with suspected GERD were tested off therapy. The wireless pH capsules were placed during upper endoscopy 6 cm above the squamocolumnar junction. RESULTS: One hundred ninety-one patients underwent a total of 198 pH studies. Fifty ambulatory pH studies (25%) were excluded from the analysis: 27 patients (14%) had insufficient data capture (less than 18 h on at least one day of monitoring), 15 patients had premature capsule release (7%), seven were repeat studies (3.5%) and one had intolerable pain requiring capsule removal (0.5%). There were 115 patients undergoing pH studies who were off medication, and 33 patients were on therapy. For the two groups of patients, results were as follows: 32 (28%) and 22 (67%) patients with normal studies on both days; 58 (50%) and five (15%) patients with abnormal studies on both days; 18 (16%) and three (9%) patients with abnormal studies on day 1 only; and seven (6%) and three (9%) patients with abnormal studies on day 2 only, respectively. CONCLUSIONS: Prolonged 48 h pH monitoring can detect more abnormal esophageal acid exposure but is associated with a significant rate of incomplete studies.     

指甲延长术在指尖损伤中的临床应用

目的总结指甲延长术在指尖损伤中的临床应用经验。方法用这种方法对8例（拇指3例,食指4例,中指1例）指尖损伤的患者进行了指甲延长术。在距甲根皮缘0.5～0.6cm处,去除一块矩形皮肤,勿损伤皮下血管网,其高度0.2～0.3cm,宽度与甲相等,将“U”形皮瓣向近端柔和推剥并缝合。结果1例术后供区发生表浅感染,经交换敷料逐渐愈合。所有甲延长的手指术后经过顺利,随访7个月～2年（平均13个月）,指甲外形较好,取得较满意的临床效果。结论在指尖损伤中应用指甲延长术,可延长指甲2～3mm,改善了手指的外形,没有发生甲生长畸形,是一种简单有效的指甲延长手术方法。     

医用水刀的临床研究进展

人们发明了各种不同的手术工具,以便减少手术的危险。连续水流切割提供了一个相对出血量少的解剖过程,并且为手术者提供了一个清晰的视角。高压水流在解剖动脉外膜和邻近于脉管的软组织器官时性能优势,选择性的结扎能够完全的保护脉管和尿路。减少手术时间。因此,深入的研究这项技术是很有必要的。     

芪月降脂片制剂处方的优化

[目的 ]优化芪月降脂片的制剂处方 .[方法 ]采用正交设计和多指标综合评分法对已筛选出的药剂辅料进行处方优化 .[结果 ]最佳制剂处方为糖粉 50 g ,辅料X 50g ,微晶纤维素 75g .[结论 ]该处方合理 ,成型性好     

靶重建放大扫描对肺孤立性结节病变的诊断意义

目的：探讨靶重建放大扫描技术对肺孤立性结节病变的诊断价值。方法：对63例患者先行常规CT平扫，选定结节处为兴趣区，行薄层靶重建放大扫描，层厚、层距为2mm，FOV为160。结果：42例恶性病变中有37例表现为深分叶，占88．1％；21例良性病变中有15例表现为浅分叶，占71．4％。恶性结节中15例内部出现条状低密度支气管征；7例出现血管集中征；8例出现空泡征；病变内部出现液化坏死13例，其中恶性病变ll例。22例出现钙化，包括12例良性病变和10例恶性病变。2例错构瘤内均见小面积脂肪性低密度影。结论：靶重建放大扫描比普通CT扫描可提供更多的信息，对良恶性病变的鉴别诊断有一定价值。恶性病变大多数为深分叶，良性病变大多数为浅分叶或无分叶。     

学习优良与不良中学生记忆特点的比较研究

目的探讨学习优良和不良中学生的记忆特点,为学习不良学生的教育提供科学依据。方法采用北京大学PES心理实验系统中的内隐记忆实验对学习优良和学习不良中学生各16名进行测试。结果学习优良和学习不良中学生的启动效应值均值分别为0.29和0.34,差异无统计学意义(P>0.05);学习优良与不良中学生的再认保持量均值分别为30.00和25.25,差异有统计学意义(P<0.01)。结论学习优良和不良中学生的内隐记忆无差异,学习优良中学生外显记忆优于学习不良中学生。提高学习不良学生的学习成绩应从外显记忆着手,同时兼顾内隐记忆的作用。     

西门子Servo-i呼吸机故障分析与对策

本文描述了西门子Servo-i呼吸机常见故障的解决方法。